Neidio i'r cynnwys
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Iaith
Pob Maes
Teitl
Awdur
Pwnc
Rhif Galw
ISBN/ISSN
Tag
Canfod
Uwch
Emerging biologics in severe a...
Dyfynnu hwn
Anfonwch hwn fel neges destun
E-bostio hwn
Argraffu
Allforio Cofnod
Allforio i RefWorks
Allforio i EndNoteWeb
Allforio i EndNote
Permanent link
Emerging biologics in severe asthma
Manylion Llyfryddiaeth
Prif Awduron:
Pavord, I
,
Hilvering, B
,
Shrimanker, R
Fformat:
Journal article
Cyhoeddwyd:
Elsevier
2016
Daliadau
Disgrifiad
Eitemau Tebyg
Dangos Staff
Eitemau Tebyg
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
gan: Shrimanker, R, et al.
Cyhoeddwyd: (2017)
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
gan: Xue, L, et al.
Cyhoeddwyd: (2015)
Management and mechanisms of severe eosinophilic asthma
gan: Shrimanker, R
Cyhoeddwyd: (2020)
Exacerbations of severe asthma in patients treated with mepolizumab
gan: Shrimanker, R, et al.
Cyhoeddwyd: (2018)
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
gan: Howell, I, et al.
Cyhoeddwyd: (2024)